|  |  | Particle Preparation | Percent Positive Cells (Mean Fluorescence Intensity) | |||
---|---|---|---|---|---|---|---|
 | Infecting Virus | Culture Treatment1 | Virus | Modification | CD4 | CD8 | CD4/8 |
1. Time Point: 3 Days | Â | Â | Â | Â | Â | Â | Â |
(a) | None | None | None | None | 51 (1400) | 38 (660) | 1.3 |
 |  |  | HIV-1 | non-engineered | 55 (1100) | 38 (580) | 1.4 |
 |  |  | HIV-1 | B7-engineered | 48 (70) | 34 (390) | 1.4 |
 |  |  | HIV-1 | B7+antiCD3 | 43 (90) | 38 (460) | 1.1 |
(b) | None | PHA/IL-2 | None | None | 50 (780) | 47 (470) | 1.1 |
 |  |  | HIV-1 | non-engineered | 54 (560) | 39 (360) | 1.4 |
 |  |  | HIV-1 | B7-engineered | 37 (95) | 45 (250) | 0.8 |
 |  |  | HIV-1 | B7+antiCD3 | 38 (100) | 34 (230) | 1.1 |
2. Time Point: 8 Days | Â | Â | Â | Â | Â | Â | Â |
(a) | None | PHA/IL-2 | None | None | 46 (1600) | 55 (370) | 0.8 |
 |  |  | HIV-1 | non-engineered | 47 (1300) | 51 (270) | 0.9 |
 |  |  | HIV-1 | B7+antiCD3 | 63 (1100) | 38 (220) | 1.6 |
(b) | HIV-MN | PHA/IL-2 | None | None | 40 (1400) | 59 (360) | 0.7 |
 |  |  | HIV-1 | non-engineered | 41 (1360) | 61 (310) | 0.7 |
 |  |  | HIV-1 | B7+antiCD3 | 47 (1260) | 58 (280) | 0.8 |
(c) | HIV-Ba-L | PHA/IL-2 | None | None | 35 (1320) | 61 (410) | 0.6 |
 |  |  | HIV-1 | non-engineered | 45 (1460) | 59 (340) | 0.8 |
 |  |  | HIV-1 | B7+antiCD3 | 49 (1100) | 54 (225) | 0.9 |